Working to empower a better immune response

Icosavax was founded in 2017 with a mission to protect at-risk populations through the discovery, development, and commercialization of vaccines for severe, life-threatening infectious diseases. We are advancing breakthrough virus-like particle (VLP) technology that enables multivalent, particle-based display of complex viral antigens, which we believe can induce broad, robust, and durable protection against the targeted viruses. Our pipeline includes clinical and preclinical development focused on respiratory syncytial virus (RSV), human metapneumovirus (hMPV), COVID-19 (SARS-CoV-2), and flu.

Our ultimate vision is to utilize our VLP technology to produce combination vaccines that may offer one or more of these potential benefits: protect against multiple viral infections, last beyond a single season, cover emerging variants, limit unwanted side effects, and significantly reduce hospitalization and death—especially in the more vulnerable elderly.

Icosavax at-a-glance
  • Developing VLP-based vaccines and combinations with the ultimate vision of creating pan-respiratory vaccines for older adults
  • Unique VLP modality with multiple potential benefits. VLPs are intentionally designed to mimic the structure of viruses to empower better immune response
  • Announced the initiation of Phase 1 for IVX-A12 for the prevention of RSV and hMPV in October of 2022
  • COVID-19 and flu programs in preclinical development
  • Continuing to expand capabilities, including a research team focused on state-of-the-art antigen design and a team optimizing our speed in manufacturing
  • Experienced team with extensive expertise in protein design and vaccine development supported by leading healthcare investors and a distinguished scientific advisory board

Executive team

Adam Simpson
Adam Simpson
Chief Executive Officer
Adam Simpson
Douglas Holtzman, PhD, MPH
Chief Scientific Officer
Adam Simpson
Niranjan Kanesa-thasan, MD, MTMH, FIDSA, FASTMH
Chief Medical Officer
Adam Simpson
Thomas Russo, CFA
Chief Financial Officer
Adam Simpson
Cassia Cearley, PhD
Chief Business Officer
Adam Simpson
Elizabeth Bekiroğlu
General Counsel
Adam Simpson
Charles Richardson, PhD
Senior Vice President, Technical Operations
Adam Simpson
Ami Shah Brown, PhD, MPH
Senior Vice President, Regulatory Affairs
Adam Simpson
Lori Stewart
Vice President, People and Culture

Board of directors

Peter Kolchinsky, PhD
Director
Heidi Kunz
Director
Mark McDade
Chair
John W. Shiver, PhD
Director
Adam Simpson
Chief Executive Officer
Ann Veneman
Director
James Wassil
Director

Scientific advisory board & key advisors

Neil King, PhD
Chair, Scientific Advisory Board
David Baker, PhD
Co-Founder
Ralf Clemens, MD
SAB Member
Barney Graham, MD, PhD
SAB Member
Christian Mandl, MD, PhD
SAB Member
Jean-Paul Prieels, PhD
SAB Member
Robin Robinson, PhD
SAB Member

Contact

Icosavax, Inc.
1930 Boren Ave, Suite 1000
Seattle, WA 98101
206.737.0085